30 May 2022 | News
This S$8 million facility in Singapore is said to be first i4.0 IVD manufacturing site at in Southeast Asia
MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, and A*STAR spinoff, focused on saving and improving lives with miRNA-powered cancer early detection tests, has announced the opening of the first industry 4.0 (i4.0) in vitro diagnostic (IVD) manufacturing facility in Southeast Asia. This S$8 million facility at JTC MedTech Hub is the largest i4.0 IVD manufacturing site at in Southeast Asia at 15,000 square feet.
Dr. ZHOU Lihan, Co-founder and CEO of MiRXES said, “This brand new I4.0 manufacturing facility will greatly advance our IVD productization and manufacturing capabilities as MiRXES accelerates the development and commercialization of our maturing pipeline of multi cancer early detection tests, pulmonary and cardiovascular disease tests, as well as our life sciences and infectious disease portfolio. This first-of-its kind facility in Southeast Asia will equip MiRXES to address the next big challenge in healthcare – cancer, and stay prepared should we need to combat another epidemic.”
The setup of this Industry 4.0-compliant IT infrastructure was supported by A*STAR’s ARTC.
The facility uses real-time data and algorithms to anticipate disruptions to supply chain and to increase the efficient translations of biotechnology research into products. This includes data for tracking capacity analysis, disruption analysis and solutions, while blockchain capability links supplier and plant data to identify areas to build resilience. These work together to create an all-encompassing self-monitoring system that ensures sustainability and minimal wastage, which MiRXES prides itself on as a responsible product manufacturer.
Australia conducts new rese...
Is Singapore ready to becom...
Laboratories in times of so...
Waters launches ACQUITY PRE...
Building reliability in healthcare
For the automation portfolio, we se
Is Singapore ready to become a glob
India develops AI tool to detect CO
China focuses on next-generation in
BioNTech to establish first South E
WHO lists China's Sinopharm COVID-1
Taiwan shares 150 oxygen concentrat
Are APAC drug formulators targeting optimal drug delivery?
1 North Bridge Road,#08-08 High Street Centre, Singapore 179094Email : email@example.com
Visit Our Digital Magazine :
© 2022 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer
Web Interface Conceived and Powered By : SCI Knowledge Interlinks